Related Experiment Video
Updated: Jul 7, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report
Lixia Yi1,2,3, Xiaoyan Zhu1,2,3, Jing Xie1,2,3
1Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Abstract:
Biliary tract cancer (BTC) is an aggressive malignancy with few options for advanced-stage treatment. The combination of PD-1/PD-L1 inhibitors with famitinib, a receptor tyrosine kinase (RTK) inhibitor, has demonstrated improved clinical outcomes in several clinical trials. We herein reported a case of a gallbladder cancer (GBC) patient with liver metastases, previously resistant to traditional chemotherapy. Remarkably, the patient achieved a complete response (CR) with a long-lasting survival benefit exceeding 3 years. This was achieved using a novel regimen combining SHR-1701, an anti-PD-L1/TGF-βR fusion protein, and famitinib, even though the patient had proficient mismatch repair (pMMR) and tested negative for PD-L1. Adverse events were limited and manageable. This is the first report of such a treatment regimen being applied in a clinical setting, suggesting that the SHR-1701 and famitinib combination may be a promising immunotherapeutic approach for patients with refractory advanced GBC.
Insights
A novel combination of SHR-1701 (anti-PD-L1/TGF-βR) and famitinib (RTK inhibitor) achieved a complete response in advanced gallbladder cancer. This treatment offers a promising new option for patients resistant to chemotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Gastroenterology
Background:
- Biliary tract cancer (BTC) is aggressive with limited advanced-stage treatment options.
- Receptor tyrosine kinase (RTK) inhibitors combined with PD-1/PD-L1 inhibitors show promise in clinical trials.
- Gallbladder cancer (GBC) is a subset of BTC requiring novel therapeutic strategies.
Observation:
- A patient with advanced GBC and liver metastases, previously resistant to chemotherapy, was treated.
- The patient received a novel regimen combining SHR-1701, an anti-PD-L1/TGF-βR fusion protein, and famitinib.
- Treatment was administered despite the patient having proficient mismatch repair (pMMR) and negative PD-L1 expression.
Findings:
- The patient achieved a complete response (CR) with a survival benefit exceeding 3 years.
- The combination therapy demonstrated efficacy even in a PD-L1 negative, pMMR GBC patient.
- Adverse events associated with the treatment were limited and manageable.
Implications:
- This case report is the first to describe the clinical application of SHR-1701 and famitinib combination.
- The SHR-1701 and famitinib combination represents a potential novel immunotherapeutic approach for refractory advanced GBC.
- This regimen may offer a new treatment avenue for GBC patients who do not respond to conventional therapies.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
